If you are a Healthcare Professional and you would like to log in to access this content, please click "Login".
You are now leaving the Lilly Medical Web site
The link you clicked on will take you to a site maintained by a third party, which is solely responsible for its content. Eli Lilly and Company does not control, influence, or endorse this site, and the opinions, claims or comments expressed on this site should not be attributed to Eli Lilly and Company. Eli Lilly and Company is not responsible for the privacy policy of any third party web sites. We encourage you to read the privacy policy of every web site you visit.
Menu closed
Please use a minimum of three unique search wordsOur search is configured to only display links relevant to answer your question. For the best results please use specific and relevant keywords that accurately reflect the information you are seeking.Please do not use this field to report adverse events or product complaints. Adverse events and product complaints should be reported. Reporting forms and information can be found at UK: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events and product complaints should also be reported to Lilly: please call Lilly UK on 01256 315 000.
Forsteo ® (teriparatide)
This information is intended for UK registered healthcare professionals only as a scientific exchange in response to your search for information. Please refer to the link for full prescribing information:
Forsteo Summary of Product Characteristics (SmPC)
Forsteo® (teriparatide): Pregnancy During Treatment
Forsteo is contraindicated for use in women who are pregnant. If pregnancy occurs, Forsteo should be discontinued.
Information
from Summary of Product Characteristics
Forsteo
is contraindicated for use during pregnancy.1
Women
of childbearing potential should use effective methods of
contraception during use of Forsteo. If pregnancy occurs, Forsteo
should be discontinued.1
Clinical
Data in Humans
The
effect of teriparatide on human fetal development has not been
studied and the potential risk for humans is unknown.
Data
from Studies in Animals
Teriparatide
was not genotoxic in a standard battery of tests. It produced no
teratogenic effects in rats, mice or rabbits. There were no important
effects observed in pregnant rats or mice administered teriparatide
at daily doses of 30 to 1000 µg/kg. However, fetal resorption
and reduced litter size occurred in pregnant rabbits administered
daily doses of 3 to 100 µg/kg. The embryotoxicity observed in
rabbits may be related to their much greater sensitivity to the
effects of PTH on blood ionised calcium compared with rodents.1
References
1.
Forsteo [summary of product characteristics]. Eli Lilly Nederland
B.V., The Netherlands.
Date of Last Review:February 05, 2020
Are you satisfied with this content?
Contact Lilly
Call or Email us
If you want to ask a Medical Information question or you want to report an adverse event or product complaint you can call us or email us at ukmedinfo@lilly.com